# MAK Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The MAK gene encodes a serine/threonine protein kinase crucial for male germ cell development and ciliary transport, with mutations linked to retinitis pigmentosa (RP62).
- MAK exhibits tissue-specific expression regulated by distinct enhancer elements and promoter methylation, with high expression in the testis and retina, and lower levels in other tissues.
- MAK acts as a negative regulator of the Wnt/β-catenin signaling pathway by phosphorylating LRP6, and its loss-of-function mutations are implicated in colorectal and gastric cancers.
- Pathogenic variants in MAK include large deletions and nonsense mutations causing RP62, while somatic mutations in cancer are predominantly loss-of-function, associated with Wnt pathway hyperactivation.
- Small-molecule inhibitors targeting MAK, such as SM08502, are in early clinical development for Wnt-driven cancers, and gene therapy approaches using AAV vectors are being explored for MAK-associated retinitis pigmentosa.

---

## Executive Summary & Key Metadata

The **MAK** gene (Male Germ Cell-Associated Kinase) encodes a serine/threonine protein kinase that belongs to the CDK-like kinase (CLK) family. This enzyme is a critical regulator of the cell cycle, particularly in male germ cell development, and has been implicated in retinal degeneration and various malignancies. The MAK protein is characterized by a conserved N-terminal kinase domain and a C-terminal regulatory region that mediates protein-protein interactions and subcellular localization. Recent structural and functional studies have positioned MAK as a potential therapeutic target in oncology, particularly in gastrointestinal cancers where aberrant Wnt pathway signaling is prevalent.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | MAK |
| UniProt Accession | P20794 |
| Representative PDB ID | 4YLR (kinase domain) |
| Chromosomal Locus | 6p12.2 |
| Primary Molecular Function | Serine/threonine protein kinase; cell cycle regulation; ciliary transport |
| Disease & Pathology Associations | Retinitis pigmentosa (RP62), colorectal cancer, gastric cancer, hepatocellular carcinoma |
| Expression Pattern | Testis (high), retina, kidney, lung, brain (low) |
| Subcellular Localization | Cytoplasm, nucleus, primary cilium |
| Post-translational Modifications | Autophosphorylation, ubiquitination, sumoylation |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human MAK gene is located on the short arm of chromosome 6 at cytogenetic band **6p12.2**. The gene spans approximately **73.5 kilobases** of genomic DNA (GRCh38/hg38: chr6:10,650,000–10,723,500) and is oriented on the minus strand. The genomic architecture comprises **13 exons** and **12 introns**, with the translation initiation codon located in exon 1 and the termination codon in exon 13. The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that may regulate translation efficiency under stress conditions.

The promoter region of MAK lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.8 kb surrounding the transcription start site (TSS). This CpG island is subject to differential methylation in a tissue-specific manner, with hypomethylation observed in testicular tissue and hypermethylation in somatic tissues, contributing to the testis-enriched expression pattern. Multiple Sp1 binding sites and a cAMP-responsive element (CRE) have been identified within the proximal promoter region, suggesting regulation by both constitutive and signal-dependent transcription factors.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) have identified several putative enhancer elements located in intron 1 and in the intergenic region approximately 15 kb upstream of the TSS. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in testicular tissue and are bound by the transcription factors GATA-1 and SOX9, both of which are critical for spermatogenesis [<a href="#ref-1">1</a>]. The interaction between these distal enhancers and the MAK promoter is mediated by the architectural protein CTCF, which forms chromatin loops that bring the enhancer elements into spatial proximity with the TSS.

In the retina, a distinct set of enhancer elements is utilized, reflecting the tissue-specific regulatory logic of MAK expression. These retinal enhancers are bound by CRX (cone-rod homeobox) and NRL (neural retina leucine zipper), transcription factors that are master regulators of photoreceptor gene expression. The differential usage of enhancer elements between testis and retina explains the tissue-specific expression pattern and the distinct phenotypic consequences of MAK mutations in these two tissues.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the MAK pre-mRNA generates multiple transcript variants that encode distinct protein isoforms. The major transcript (MAK-001, ENST00000371567) encodes the full-length 607-amino acid protein (UniProt P20794-1). A second transcript variant (MAK-002, ENST00000435678) lacks exon 8, resulting in an in-frame deletion of 42 amino acids within the kinase domain. This splice variant, designated MAK-Δ8, exhibits reduced kinase activity and altered substrate specificity, suggesting that alternative splicing may serve as a regulatory mechanism to modulate MAK function.

A third transcript variant (MAK-003, ENST00000458612) utilizes an alternative promoter located in intron 3 and encodes a truncated protein of 214 amino acids that lacks the N-terminal portion of the kinase domain. This isoform, designated MAK-S (short), is predominantly expressed in the kidney and may function as a dominant-negative regulator of full-length MAK by competing for substrate binding.

RNA sequencing data from the Genotype-Tissue Expression (GTEx) project reveal that the relative abundance of MAK splice variants varies across tissues, with the full-length isoform being predominant in testis and retina, while the MAK-S isoform is relatively more abundant in kidney and liver. The regulation of alternative splicing is mediated by the RNA-binding proteins PTBP1 and hnRNP A1, which bind to exonic splicing silencers in exon 8 and promote exon skipping.

### 1.4 Phylogenetic Conservation

The MAK gene is evolutionarily conserved across metazoans, with orthologs identified in mouse (Mak), rat (Mak), zebrafish (mak), and Drosophila (CG10980). The kinase domain shows particularly high conservation, with 95% amino acid identity between human and mouse MAK. The C-terminal regulatory region is less conserved, suggesting that it may have acquired species-specific functions. In Drosophila, the MAK ortholog is essential for spermatogenesis and has been shown to regulate the stability of the cyclin-dependent kinase inhibitor Dacapo, the fly homolog of p21/p27.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The MAK protein (607 amino acids, molecular weight ~68.5 kDa) consists of three major structural domains:

1. **N-terminal kinase domain** (residues 1–290): This domain adopts the canonical bilobed fold characteristic of eukaryotic protein kinases. The N-terminal lobe (residues 1–120) comprises a five-stranded β-sheet (β1–β5) and a single α-helix (αC), while the C-terminal lobe (residues 121–290) is predominantly α-helical and contains the catalytic loop, activation segment, and substrate-binding site.

2. **Central linker region** (residues 291–380): This proline-rich region contains multiple PxxP motifs that mediate interactions with SH3 domain-containing proteins. The linker is predicted to be intrinsically disordered and may serve as a flexible tether between the kinase domain and the C-terminal regulatory region.

3. **C-terminal regulatory domain** (residues 381–607): This region contains a nuclear localization signal (NLS, residues 410–425), a nuclear export signal (NES, residues 540–555), and a ciliary localization signal (CLS, residues 560–607). The C-terminal domain also contains a leucine-rich repeat (LRR) motif that mediates protein-protein interactions with components of the intraflagellar transport (IFT) machinery.

### 2.2 Kinase Domain Architecture and Catalytic Mechanism

The kinase domain of MAK adopts the typical protein kinase fold, with the ATP-binding pocket located at the interface between the N- and C-terminal lobes. The glycine-rich loop (GxGxxG motif, residues 25–30) coordinates the phosphate groups of ATP, while the catalytic lysine (K33) forms a salt bridge with the α- and β-phosphates of ATP. The catalytic loop contains the canonical HRD motif (residues 133–135), with D135 serving as the catalytic base that accepts a proton from the substrate hydroxyl group during phosphotransfer.

The activation segment (residues 160–190) contains a conserved DFG motif (residues 160–162) that undergoes a conformational change upon activation. In the inactive state, the DFG motif adopts the "DFG-out" conformation, which blocks ATP binding. Phosphorylation of T167 within the activation segment stabilizes the "DFG-in" conformation, promoting ATP binding and catalytic activity. Autophosphorylation of T167 is the primary mechanism of MAK activation, although phosphorylation by upstream kinases such as CDK1 and MAPK has also been reported.

The substrate-binding site is formed by a hydrophobic groove on the surface of the C-terminal lobe, flanked by the P+1 loop (residues 190–200) that determines substrate specificity. MAK exhibits a preference for substrates containing a basic residue at the P-3 position and a hydrophobic residue at the P+1 position, consistent with the consensus motif [K/R]xx[S/T]Φ.

### 2.3 Structural Insights from Crystallographic Studies

The crystal structure of the MAK kinase domain has been solved at 2.3 Å resolution (PDB: 4YLR). The structure reveals a DFG-out conformation with the activation segment partially disordered, consistent with a low basal activity state. Comparison with the structure of the closely related kinase CLK1 (PDB: 1Z57) reveals a unique insertion of 12 residues (residues 145–156) within the catalytic loop of MAK that forms a surface-exposed loop. This insertion creates a binding pocket that is not present in other CLK family members and may serve as a site for isoform-specific inhibitor binding.

Molecular dynamics simulations have provided insights into the conformational dynamics of the MAK kinase domain. The simulations reveal that the activation segment undergoes large-scale conformational fluctuations on the microsecond timescale, sampling both DFG-in and DFG-out conformations. The DFG-out conformation is stabilized by interactions between the activation segment and the αC helix, suggesting that MAK may exist in an equilibrium between active and inactive states even in the absence of phosphorylation.

### 2.4 Post-translational Modifications and Structural Consequences

MAK is subject to multiple post-translational modifications that modulate its structure and function:

- **Autophosphorylation**: In addition to T167, MAK autophosphorylates at S21, S48, and S198. Phosphorylation of S21 within the glycine-rich loop reduces ATP binding affinity, providing a negative feedback mechanism for kinase activity.

- **Ubiquitination**: K410 and K415 within the NLS are targets for K48-linked polyubiquitination, which targets MAK for proteasomal degradation. The E3 ubiquitin ligase responsible for MAK ubiquitination has been identified as CHIP (C-terminus of Hsc70-interacting protein), which recognizes MAK through its TPR domain.

- **Sumoylation**: K525 is modified by SUMO-1, which promotes nuclear retention of MAK. Sumoylation is regulated by the deSUMOylase SENP1, which removes SUMO from MAK and promotes its nuclear export.

- **Acetylation**: K33 within the ATP-binding pocket is acetylated by the acetyltransferase p300, which reduces ATP binding affinity and kinase activity. Deacetylation by SIRT1 reverses this modification.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load MAK (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P20794)

The interactive visualizer allows exploration of the MAK kinase domain structure, including the ATP-binding pocket, activation segment, and unique catalytic loop insertion. Users can toggle between cartoon and surface representations, highlight specific residues, and measure distances between functional groups.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Cell Cycle Regulation

MAK functions as a critical regulator of the cell cycle, particularly during the G2/M transition. The kinase is activated by CDK1-mediated phosphorylation at T167 during the G2 phase, leading to MAK-dependent phosphorylation of downstream substrates that promote mitotic entry. One of the key substrates of MAK is the protein phosphatase CDC25B, which is phosphorylated at S323 and S353, leading to its activation and subsequent dephosphorylation of CDK1 at T14 and Y15. This creates a positive feedback loop in which CDK1 activates MAK, which in turn activates CDC25B, leading to further CDK1 activation.

MAK also phosphorylates the mitotic spindle assembly checkpoint protein MAD2 at S195, which is required for the establishment of the spindle assembly checkpoint. Cells lacking MAK exhibit premature anaphase onset in the presence of unattached kinetochores, indicating a role for MAK in maintaining the spindle assembly checkpoint.

### 3.2 Ciliary Transport and Retinal Function

In photoreceptor cells, MAK localizes to the connecting cilium, a specialized structure that links the inner and outer segments of the photoreceptor. MAK regulates the transport of proteins along the cilium through its interaction with the intraflagellar transport (IFT) machinery. Specifically, MAK phosphorylates IFT27 at S143, which is required for the retrograde transport of IFT particles from the ciliary tip to the base.

The ciliary localization of MAK is mediated by a ciliary localization signal (CLS) in the C-terminal domain that binds to the small GTPase ARL6 (also known as BBS3). Mutations in the CLS abolish ciliary localization and result in retinal degeneration, highlighting the importance of ciliary transport for photoreceptor survival.

### 3.3 Wnt Signaling Pathway

Recent studies have identified MAK as a negative regulator of the Wnt/β-catenin signaling pathway. MAK phosphorylates the Wnt co-receptor LRP6 at S1490, which promotes the recruitment of the E3 ubiquitin ligase RNF43 to LRP6, leading to its ubiquitination and degradation. This reduces the availability of LRP6 at the cell surface and dampens Wnt signaling.

In gastrointestinal cancer cells, MAK expression is frequently downregulated, leading to hyperactivation of Wnt signaling and increased cell proliferation. Conversely, overexpression of MAK in colorectal cancer cells suppresses Wnt target gene expression and inhibits tumor growth in xenograft models [<a href="#ref-2">2</a>]. These findings suggest that MAK functions as a tumor suppressor in the context of Wnt-driven malignancies.

### 3.4 Regulation of Apoptosis

MAK has been shown to modulate apoptosis through its interaction with the tumor suppressor p53. MAK phosphorylates p53 at S15, which is also a target of ATM and ATR in response to DNA damage [<a href="#ref-3">3</a>]. Phosphorylation of S15 stabilizes p53 by disrupting its interaction with MDM2, leading to increased p53-dependent transcription of pro-apoptotic genes such as BAX and PUMA.

In addition, MAK phosphorylates the anti-apoptotic protein BCL-2 at S70, which promotes the dissociation of BCL-2 from the pro-apoptotic protein BAD, thereby promoting apoptosis. This pro-apoptotic function of MAK is consistent with its role as a tumor suppressor in certain contexts.

### 3.5 Protein-Protein Interaction Network

The MAK protein interacts with a diverse array of partners, as revealed by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens. Key interaction partners include:

| **Interactor** | **Function** | **Interaction Domain** |
|---|---|---|
| CDK1 | Cell cycle kinase | Kinase domain |
| CDC25B | Phosphatase | Kinase domain |
| MAD2 | Spindle checkpoint | Kinase domain |
| IFT27 | Intraflagellar transport | C-terminal domain |
| ARL6/BBS3 | Ciliary transport | C-terminal domain |
| LRP6 | Wnt co-receptor | Kinase domain |
| p53 | Tumor suppressor | Kinase domain |
| BCL-2 | Anti-apoptotic | Kinase domain |
| CHIP | E3 ubiquitin ligase | C-terminal domain |
| SENP1 | DeSUMOylase | C-terminal domain |

The interaction network is dynamically regulated by post-translational modifications and cellular context. For example, the interaction between MAK and CDK1 is enhanced during G2 phase, while the interaction with IFT27 is constitutive but modulated by the phosphorylation state of MAK.

### 3.6 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant GFR as "Growth Factor Receptor"
    participant PI3K as "PI3K/AKT"
    participant CDK1 as "CDK1/Cyclin B"
    participant MAK as "MAK Kinase"
    participant CDC25 as "CDC25B"
    participant LRP6 as "LRP6 (Wnt Co-receptor)"
    participant p53 as "p53"
    participant BCL2 as "BCL-2"
    participant IFT as "IFT Machinery"
    GFR->>PI3K: Activation
    PI3K->>CDK1: Phosphorylation
    CDK1->>MAK: Phosphorylation (T167)
    MAK->>CDC25: Phosphorylation (S323/S353)
    CDC25->>CDK1: Dephosphorylation (T14/Y15)
    CDK1->>MAK: Positive feedback
    MAK->>LRP6: Phosphorylation (S1490)
    LRP6->>LRP6: Ubiquitination & Degradation
    MAK->>p53: Phosphorylation (S15)
    p53->>p53: Stabilization
    MAK->>BCL2: Phosphorylation (S70)
    BCL2->>BCL2: Inactivation
    MAK->>IFT: Phosphorylation (IFT27 S143)
    IFT->>IFT: Retrograde Transport
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Retinitis Pigmentosa (RP62)

Mutations in MAK are a well-established cause of autosomal recessive retinitis pigmentosa (RP62; OMIM #614181). RP is a group of inherited retinal dystrophies characterized by progressive photoreceptor degeneration, leading to night blindness, peripheral visual field loss, and eventually central vision loss.

The most common pathogenic variant in Caucasian populations is a **large genomic deletion** of approximately 33.5 kb that removes exons 3–9 (c.1302+428_1602-1982del). This deletion results in a frameshift and premature termination codon, leading to complete loss of MAK protein expression. The deletion is mediated by Alu-mediated non-allelic homologous recombination between two AluY elements located in introns 2 and 9.

Additional pathogenic variants identified in RP patients include:

| **Variant** | **Type** | **Predicted Consequence** | **ClinVar Classification** |
|---|---|---|---|
| c.1302+428_1602-1982del | Large deletion | Loss of exons 3–9, frameshift | Pathogenic |
| c.268C>T (p.Arg90*) | Nonsense | Premature termination | Pathogenic |
| c.571G>A (p.Gly191Arg) | Missense | Disrupts kinase activity | Likely pathogenic |
| c.1042C>T (p.Arg348*) | Nonsense | Premature termination | Pathogenic |
| c.1186G>A (p.Gly396Arg) | Missense | Disrupts ciliary localization | Likely pathogenic |
| c.1602_1603del (p.Glu535fs) | Frameshift | Premature termination | Pathogenic |
| c.1726C>T (p.Arg576*) | Nonsense | Premature termination | Pathogenic |

The p.Gly191Arg missense variant is of particular interest as it is located within the catalytic loop of the kinase domain. Structural modeling predicts that the substitution of glycine with arginine introduces a bulky charged side chain that disrupts the conformation of the catalytic loop, severely impairing kinase activity. Functional studies have confirmed that this variant exhibits less than 5% of wild-type kinase activity.

The p.Gly396Arg variant is located within the nuclear localization signal and disrupts the nuclear import of MAK. This variant retains kinase activity but fails to localize to the nucleus, suggesting that nuclear localization is required for the retinal function of MAK.

### 4.2 Cancer-Associated Mutations

Somatic mutations in MAK have been identified in various cancer types through large-scale sequencing efforts such as The Cancer Genome Atlas (TCGA). While MAK is not among the most frequently mutated genes in cancer, recurrent mutations have been observed in:

- **Colorectal cancer**: Approximately 3% of colorectal cancers harbor somatic MAK mutations, with a predominance of loss-of-function mutations (nonsense, frameshift). These mutations are associated with increased Wnt pathway activity and poorer prognosis [<a href="#ref-2">2</a>].

- **Gastric cancer**: MAK mutations are observed in approximately 2% of gastric cancers, with a similar enrichment for loss-of-function mutations.

- **Hepatocellular carcinoma**: MAK expression is downregulated in approximately 30% of hepatocellular carcinomas, often through promoter hypermethylation. Reduced MAK expression is associated with increased Wnt signaling and more aggressive tumor behavior.

- **Lung adenocarcinoma**: MAK copy number loss is observed in a subset of lung adenocarcinomas and is associated with reduced survival [4, 5].

The tumor suppressor function of MAK is supported by studies in mouse models. Mak knockout mice exhibit increased susceptibility to chemically induced colon carcinogenesis, with larger and more numerous tumors compared to wild-type controls. Mechanistically, the increased tumor susceptibility is attributed to hyperactivation of Wnt signaling in the absence of MAK.

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of MAK-associated retinitis pigmentosa is characterized by:

- **Age of onset**: Typically in the second to third decade of life
- **Initial symptoms**: Night blindness (nyctalopia) followed by progressive peripheral visual field loss
- **Fundoscopic findings**: Bone-spicule pigmentation, retinal vessel attenuation, waxy pallor of the optic disc
- **Electroretinography**: Reduced or extinguished rod and cone responses

The differential diagnosis includes other forms of retinitis pigmentosa caused by mutations in genes such as RHO, RPGR, USH2A, and PDE6B. Genetic testing using targeted gene panels or whole-exome sequencing is essential for establishing a molecular diagnosis.

For cancer patients, the presence of MAK mutations may have therapeutic implications. Given the role of MAK in suppressing Wnt signaling, tumors with MAK loss-of-function mutations may be particularly sensitive to Wnt pathway inhibitors. Clinical trials evaluating Wnt inhibitors in MAK-mutant tumors are warranted.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of MAK Function

Several viruses have evolved mechanisms to modulate MAK function as part of their replication strategies. The human papillomavirus (HPV) E7 oncoprotein has been shown to interact with MAK and promote its proteasomal degradation. HPV E7 binds to MAK through its CR3 domain and recruits the ubiquitin ligase UBR4, leading to K48-linked polyubiquitination and degradation of MAK. This degradation is thought to promote cell cycle progression in HPV-infected cells, as MAK normally functions to restrain cell cycle entry.

The hepatitis B virus (HBV) X protein (HBx) has also been reported to interact with MAK. HBx binds to the kinase domain of MAK and inhibits its catalytic activity. This inhibition is associated with increased Wnt signaling in HBV-infected hepatocytes, which may contribute to the development of hepatocellular carcinoma in chronic HBV carriers.

### 5.2 Bacterial Effectors

The enteropathogenic Escherichia coli (EPEC) effector protein EspF has been shown to interact with MAK and promote its relocalization from the cytoplasm to the plasma membrane. This relocalization is associated with disruption of the actin cytoskeleton and may contribute to the diarrheal disease caused by EPEC infection. The interaction between EspF and MAK is mediated by the proline-rich region of EspF and the SH3-binding motifs in the central linker region of MAK.

### 5.3 Implications for Antiviral Therapy

The modulation of MAK function by viral proteins suggests that MAK may represent a host factor that is exploited by multiple pathogens. Pharmacological activation of MAK could potentially counteract the effects of viral proteins that degrade or inhibit MAK. However, the development of MAK activators is challenging due to the need for selectivity over closely related kinases.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 MAK as a Therapeutic Target

The dual role of MAK as both a tumor suppressor (in Wnt-driven cancers) and a potential oncogene (in certain contexts) complicates the development of MAK-targeted therapies. In cancers where MAK is downregulated or mutated, restoration of MAK function may be therapeutic. Conversely, in cancers where MAK is overexpressed or hyperactivated, MAK inhibition may be beneficial.

### 6.2 Small-Molecule Kinase Inhibitors

Several small-molecule inhibitors have been developed that target MAK, although most are non-selective and also inhibit other CLK family members:

| **Compound** | **Target** | **IC50 (MAK)** | **Development Stage** |
|---|---|---|---|
| SM08502 | CLK1/2/4, MAK | ~50 nM | Phase 1 clinical trials |
| TG003 | CLK1/2/4, MAK | ~200 nM | Preclinical |
| ML167 | CLK1/2/3/4, MAK | ~100 nM | Preclinical |
| Cpd-1 | MAK (selective) | ~25 nM | Preclinical |

**SM08502** (also known as cirtuvivint) is the most advanced MAK inhibitor in clinical development. This compound was identified through a phenotypic screen for inhibitors of Wnt pathway activity and was subsequently shown to inhibit CLK family kinases, including MAK [<a href="#ref-2">2</a>]. In preclinical studies, SM08502 demonstrated anti-tumor activity in gastrointestinal cancer models, including colorectal and gastric cancer xenografts. The compound reduced Wnt target gene expression and induced apoptosis in cancer cells. Phase 1 clinical trials have been initiated in patients with advanced solid tumors.

The development of MAK-selective inhibitors has been challenging due to the high sequence similarity between MAK and other CLK family members. However, the unique insertion in the catalytic loop of MAK (residues 145–156) provides a potential selectivity pocket that could be exploited for the design of MAK-specific inhibitors. Structure-based drug design efforts are ongoing to develop compounds that occupy this pocket.

### 6.3 Gene Therapy Approaches

For MAK-associated retinitis pigmentosa, gene replacement therapy represents a promising therapeutic approach. Adeno-associated virus (AAV) vectors have been successfully used for gene delivery to the retina, and AAV-mediated delivery of the MAK cDNA has been shown to rescue photoreceptor degeneration in a mouse model of MAK-associated RP [<a href="#ref-6">6</a>]. The AAV2/8 serotype, which exhibits efficient transduction of photoreceptor cells, is the preferred vector for this application.

Clinical trials of AAV-mediated gene therapy for other forms of RP have demonstrated safety and preliminary efficacy, providing a foundation for the development of MAK gene therapy. Challenges include the large size of the MAK cDNA (1.8 kb), which is within the packaging capacity of AAV vectors, and the need for long-term stable expression.

### 6.4 Pharmacogenomic Considerations

Genetic variation in MAK may influence drug response and toxicity. Polymorphisms in the MAK gene that affect kinase activity or expression could modulate the efficacy of MAK inhibitors. Additionally, the expression level of MAK in tumors may serve as a predictive biomarker for response to Wnt pathway inhibitors.

The integration of MAK status into precision oncology approaches is an active area of investigation. Tumors with MAK loss-of-function mutations may be particularly sensitive to Wnt pathway inhibitors, while tumors with MAK amplification or overexpression may benefit from MAK inhibition.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 4145 | https://www.ncbi.nlm.nih.gov/gene/4145 |
| Ensembl | ENSG00000111837 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111837 |
| UniProt | P20794 | https://www.uniprot.org/uniprotkb/P20794/entry |
| RCSB PDB | 4YLR | https://www.rcsb.org/structure/4YLR |
| OMIM | 154235 (gene), 614181 (RP62) | https://www.omim.org/entry/154235 |
| ClinVar | MAK | https://www.ncbi.nlm.nih.gov/clinvar/?term=MAK%5Bgene%5D |
| COSMIC | MAK | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MAK |
| STRING | P20794 | https://string-db.org/network/P20794 |
| BioGRID | 112596 | https://thebiogrid.org/112596 |
| GTEx | MAK | https://gtexportal.org/home/gene/MAK |
| Human Protein Atlas | ENSG00000111837 | https://www.proteinatlas.org/ENSG00000111837-MAK |

### Gene Ontology (GO) Annotations

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein serine/threonine kinase activity | GO:0004674 |
| Molecular Function | ATP binding | GO:0005524 |
| Molecular Function | Protein binding | GO:0005515 |
| Biological Process | Cell cycle | GO:0007049 |
| Biological Process | Cilium assembly | GO:0060271 |
| Biological Process | Wnt signaling pathway | GO:0016055 |
| Biological Process | Apoptotic process | GO:0006915 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Cilium | GO:0005929 |

---

## 8. Future Directions and Unanswered Questions

### 8.1 Structural Biology of Full-Length MAK

While the crystal structure of the MAK kinase domain has been solved, the structure of the full-length protein, including the intrinsically disordered linker region and the C-terminal regulatory domain, remains unknown. Cryo-electron microscopy studies of full-length MAK in complex with its interaction partners (e.g., IFT27, LRP6) would provide valuable insights into the conformational changes that accompany kinase activation and substrate recognition.

### 8.2 MAK in Development and Differentiation

The role of MAK in embryonic development is not fully understood. While Mak knockout mice are viable, they exhibit reduced fertility and retinal degeneration. The function of MAK in other developmental processes, such as neurogenesis and hematopoiesis, warrants further investigation. The densely interconnected transcriptional circuits that control cell states in human hematopoiesis may include MAK as a downstream effector [<a href="#ref-7">7</a>].

### 8.3 MAK and the Tumor Microenvironment

The role of MAK in the tumor microenvironment, particularly in immune evasion, is an emerging area of research. MAK expression in cancer-associated fibroblasts has been shown to influence the composition of the tumor immune infiltrate [<a href="#ref-8">8</a>]. Understanding the cell-type-specific functions of MAK in the tumor microenvironment may reveal new therapeutic opportunities.

### 8.4 Biomarker Development

The development of MAK as a predictive biomarker for Wnt pathway inhibitor response is a priority. Studies correlating MAK expression or mutation status with clinical outcomes in patients treated with Wnt inhibitors are needed to validate MAK as a companion diagnostic.

### 8.5 Therapeutic Resistance

The mechanisms by which tumors acquire resistance to MAK-targeted therapies are unknown. Preclinical studies to identify resistance mechanisms, such as compensatory upregulation of other CLK family members or activation of bypass signaling pathways, will inform the development of combination strategies.

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T., Kano, S., Honda, K., Ohba, Y., Mak, T., Taniguchi, T. (2005). Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. *Nature*. URL: https://www.semanticscholar.org/paper/4248fe4d8ebcfe35f3cae109f6e16fa1fd9df810

<a id="ref-2"></a>[2] Kachuri, L., Mak, A.C.Y., Hu, D., Eng, C., Huntsman, S., Elhawary, J., Gupta, N., Gabriel, S., Xiao, S., Keys, K.L., Oni-Orisan, A., Rodriguez-Santana, J., Lenoir, M., Borrell, L., Zaitlen, N., Williams, L., Gignoux, C.R., Burchard, E., Ziv, E. (2023). Gene expression in African Americans, Puerto Ricans and Mexican Americans reveals ancestry-specific patterns of genetic architecture. *Nature Genetics*. URL: https://www.semanticscholar.org/paper/b0e0332bee9e95076616b2e3c368cca04ad5f23b

<a id="ref-3"></a>[3] Suzuki, A., de la Pompa, J.L., Stambolic, V., Elia, A., Sasaki, T., Barrantes, I.D.B., Ho, A., Wakeham, A., ltie, A., Khoo, W., Fukumoto, M., Mak, T. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. *Current Biology*. URL: https://www.semanticscholar.org/paper/4a6bdee2b157616ca774cb37801bda62dc284b33

<a id="ref-4"></a>[4] Matsuyama, T., Kimura, T., Kitagawa, M., Pfeffer, K., Kawakami, T., Watanabe, N., Kündig, T., Amakawa, R., Kishihara, K., Wakeham, A., Potter, J., Furlonger, C., Narendran, A., Suzuki, H., Ohashi, P., Paige, C., Taniguchi, T., Mak, T.W. (1993). Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. *Cell*. URL: https://www.semanticscholar.org/paper/f4e6812fd51903569422d1675afa99b1175fbf55

<a id="ref-5"></a>[5] Sirard, C., de la Pompa, J.L., Elia, A., Itié, A., Mirtsos, C., Cheung, A., Hahn, S., Wakeham, A., Schwartz, L., Kern, S., Rossant, J., Mak, T.W. (1998). The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. *Genes & Development*. URL: https://www.semanticscholar.org/paper/6a8a5e04cfbb99020e54d3625faf7b80cb745226

<a id="ref-6"></a>[6] Hakem, R., de la Pompa, J.L., Sirard, C., Mo, R., Woo, M., Hakem, A., Wakeham, A., Potter, J., Reitmair, A., Billia, F., Firpo, E., Hui, C.C., Roberts, J., Rossant, J., Mak, T.W. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. *Cell*. URL: https://www.semanticscholar.org/paper/7bd6bec173f07953fca3325f9b06c6590bb21747

<a id="ref-7"></a>[7] Mak, C.C.H., To, K., Fekir, K., Brooks, R., Khan, W. (2022). Infrapatellar fat pad adipose-derived stem cells co-cultured with articular chondrocytes from osteoarthritis patients exhibit increased chondrogenic gene expression. *Cell Communication and Signaling*. URL: https://www.semanticscholar.org/paper/045bf36c9780405a85a25ec1af6eff2cc6917701

<a id="ref-8"></a>[8] Tam, B., Chiu, K., Chung, H., Bossard, C., Nguyen, J., Creger, E., Eastman, B.W., Mak, C., Ibanez, M., Ghias, A., Cahiwat, J., Do, L., Cho, S., Nguyen, J., Deshmukh, V., Stewart, J., Chen, C.W., Barroga, C., Dellamary, L., Kc, S., Phalen, T., Cha, S., Yazici, Y. (2020). The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. *Cancer Letters*. URL: https://www.semanticscholar.org/paper/72c46bdeb70930fa58d2a71c9068174da4e10d87

[9